About 90% of U.S. adults meet the criteria for a newly recognized syndrome that comes from a combination of heart disease, ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...

Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...

Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with significantly longer disease-free survival than placebo (24 months: 77% vs. 68%; ...